Christopher Sumey

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

Robert C. Doebele, Xian Lu, Christopher Sumey et al. · Cancer · 2012 · 278 citations · Full text

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.

Ticiana Leal, Yating Wang, Afshin Dowlati et al. · Journal of Clinical Oncology · 2020 · 131 citations

Ecog-acrin Ea5161, Immunotherapy, Maintenance Nivolumab +17

Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study

Steven Powell, Kathryn A. Gold, Mark M. Gitau et al. · Journal of Clinical Oncology · 2020 · 117 citations · Full text